Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A randomized, double-blind, placebo-controlled, phase 2a study to assess the clinical efficacy of ISIS721744, a second-generation ligand-conjugated antisense inhibitor of prekallikrein, in patients with hereditary angioedema

This is a study to test whether an investigational drug given by injection every four weeks will reduce swelling episodes in patients with hereditary angioedema (HAE).
Joshua Adams at jadams4@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04030598
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Hereditary angioedema
18 years of age and above
able to use 1 acute medication to treat angioedema attacks
females non-pregnant and not planning to get pregnant
males must be using contraceptive method
Exclusion Criteria:
use of short-term prophylaxis for angioedema attacks
concurrent diagnosis of any othe type of recurrent angioedema
abnormalities in screening lab values
active infection
known history positive for HIV, hep C or B
Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA